52U.F HYLORIS PHARMA. S.A.

Healthcare Biotechnology Frankfurt Exchange
4.12 EUR
Close of Nov 11, 2026
3.39 8.14
Market cap
EUR 115M
P/E
-
P/B
4.67x
ROE
-23.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 52U.F undervalued?

Graham number

The Graham number of HYLORIS PHARMA. S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

HYLORIS PHARMA. S.A. fundamental analysis

No fundamental analysis for HYLORIS PHARMA. S.A. yet.

HYLORIS PHARMA. S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About HYLORIS PHARMA. S.A.

Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias; and Valacyclovir oral suspen…

Full company profile